FDA granted key breast cancer approval for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Datroway (datopotamab deruxtecan-dlnk), establishing a first-line option for patients with triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. The decision is positioned as Datroway’s third approval and adds momentum to the company’s TROP2 franchise. The authorization is based on phase 3 data from TROPION-Breast02, which showed a statistically significant improvement in overall survival versus investigator’s-choice chemotherapy, alongside stronger objective response rates. The label framework targets a defined treatment constraint—exclusion from PD-1/PD-L1 candidates—rather than broadening indiscriminately. This approval arrives as the competitive ADC–immunotherapy landscape heats up, with companies seeking differentiation via biomarker selection, line-of-therapy strategy, and combinations.